Abstract 1678P
Background
Breast cancer have a significant impact on the life of married couples. Partners are faced with many challenges such as the heavy treatments and the body changes associated with the disease.
Methods
We conducted a study including patients treated for breast cancer in Salah Azaiz Institute. The aim was to evaluate the impact of cancer on the couple's relationship. The patients agreed to answer a marital adjustment questionnaire (MAQ).
Results
The study included 53 patients with a mean age of 52.25 years, ranging from 34 to 72 years. At the time of the study, 83% (n=44) had been married for between 3 and 60 years, with a mean of 22.5 years and a standard deviation of 11.4. The age at marriage was 27.80±6.9 years, with extremes ranging from 15 to 50 years. Fifteen per cent of patients had no children, and the number of children ranged from 1 to 5, with an average of 2.2. The average age difference between the married women and their partners was 5.3 years, with extremes ranging from one year to 23 years. More than half of the population studied in couple had intimacy problems (n=34),. The mean marital agreement score was 81.65 [41-120]. Eight couples no longer engaged in activities together outside the home and 39.5% (n=21) of them very little. Twenty-nine patients (54.7%) said that they almost never showed affection to their partners. The study of sexual activity showed an abstinence rate of 35.8% (n=19) compared to versus 0% before cancer. A quarter of our population had less than two sexual encounters per month after the disease, compared with 20.8% (n=11) and only 10% had more than 4 intercourses per month compared with 50.9% (n=27), before treatment. Twenty patients (37.3%) frequently disagreed about the sexual relationship. Fifty-four per cent (n=29) of the patients interviewed stated that they had a sexual complaint at the time of the survey: Among them, 32% (n=17) had spoken to their partners about the subject. Twenty-two (n=12) of the patients said they could no longer confide in their partner.
Conclusions
Breast cancer requires adjustments in married life, but with mutual support and open communication, couples can overcome these challenges together.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1687P - Perceptions of genetic testing and lived experiences in women with locally advanced or metastatic ovarian cancer: A focus on BRCAm and BRCAwt patients
Presenter: María Jesús Rubio Pérez
Session: Poster session 11
1688P - Psychosocial distress and spirituality among elderly patients with cancer in Nigeria
Presenter: Zainab Ogunjimi
Session: Poster session 11
1689TiP - The social stigma of smokers and patients with lung cancer: Detection of phoenomenon and testing of EMDR (eye movement desensitization and reprocessing) intervention
Presenter: Domenico Galetta
Session: Poster session 11
1692P - A phase Ib/IIa trial to evaluate the safety and efficacy of PM8002/ BNT327, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced renal cell carcinoma
Presenter: Xinan Sheng
Session: Poster session 11
1693P - CaboPoint: Final results from a phase II study of cabozantinib after checkpoint inhibitor (CPI) combinations in patients with advanced renal cell carcinoma (aRCC)
Presenter: Laurence Albiges
Session: Poster session 11
1695P - Phase I LITESPARK-018: Dose escalation study of belzutifan in advanced pretreated clear cell renal cell carcinoma (ccRCC)
Presenter: Ulka Vaishampayan
Session: Poster session 11
1696P - A phase I/ II trial of pazopanib (Paz) alternating (alt) with bevacizumab (Bev) in treatment-naïve metastatic clear cell renal cell carcinoma (mccRCC) patients (pts): Phase II results
Presenter: Saby George
Session: Poster session 11
1697P - Phase II randomized double-blind trial of axitinib (Axi) +/- PF 04518600, an OX40 antibody (PFOX) after PD1/PDL1 antibody (IO) therapy (Tx) in metastatic renal cell carcinoma (mRCC): Final analysis
Presenter: Sarmad Sadeghi
Session: Poster session 11
1698P - Avelumab + axitinib (Ave + Axi) vs sunitinib (Sun) in advanced renal cell carcinoma (aRCC): Final analysis of patient (pt)-reported outcomes (PROs) and quality-adjusted time without symptoms or toxicity (Q-TWiST)
Presenter: Balaji Venugopal
Session: Poster session 11